Nifekalant clinical trials
How each study uses nifekalant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nifekalant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Beijing Anzhen Hospital (1) · Second Affiliated Hospital of Nanchang University (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses nifekalant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac SurgeryRecruitingPhase 3Beijing Anzhen HospitalNCT05169866Written as Nifekalant
- Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency AblationStatus unknownPhase 4Second Affiliated Hospital of Nanchang UniversityNCT04209959Written as nifekalant
- Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.Status unknownPhase 4Sichuan Baili Pharmaceutical Co., Ltd.NCT03855826Written as Nifekalant hydrochloride
Codes
What other systems call nifekalant · ClinicalTrials.gg INT003654
- MeSH (NLM) C076259nifekalantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5VZ7GZM43ENIFEKALANTConfirmed FDA, NLM, Wikidata
- Wikidata Q671772nifekalantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C75132NifekalantOne source FDA
- DrugBank DB16008One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C076259 | nifekalant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5VZ7GZM43E | NIFEKALANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q671772 | nifekalant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C75132 | Nifekalant | One source FDA |
| DrugBank | DB16008 | — | One source Wikidata |
Also registered as nifekalant hydrochloride (UNII TPP5R0MDQS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.